Drug Price Competition and Patent Term Restoration Act of 1984 (Hatch-Waxman Act)

Mandatory Reading:

• Regulatory Affairs (Reg)
• Intellectual Property (IP)
• Quality Assurance (QA)
• Legal Department

Work Suggestions:

• Reg: Ensure the company's drug applications comply with the new drug application procedures and bioequivalence standards.
• IP: Monitor patent term extensions and the impact on the company's patent strategy.
• QA: Verify that manufacturing processes meet the identity, strength, quality, and purity requirements.
• Legal Department: Advise on patent infringement issues and the legal implications of abbreviated new drug applications.

Scope of Application:
The Drug Price Competition and Patent Term Restoration Act of 1984 applies to chemical drugs, including new molecular entities and generic drugs, in the United States. It is intended for regulatory bodies, pharmaceutical companies, and legal entities involved in drug development and approval processes.

Key Points Summary:

1. Abbreviated New Drug Applications (ANDAs): The Act allows for the streamlined approval of generic drugs by submitting abbreviated applications showing bioequivalence to the listed drug, without repeating costly and time-consuming clinical trials.

2. Patent Term Restoration: Offers a mechanism to extend the effective patent life of a drug to partially compensate for the time lost during the regulatory review process, up to a maximum of five years.

3. Data Exclusivity: Provides a period of data exclusivity, during which the FDA cannot approve ANDAs for other companies that rely on the innovator's safety and efficacy data.

4. Patent Certification: Requires ANDA applicants to certify about the listed drug's patents or periods of exclusivity, which can trigger a patent infringement lawsuit.

5. Regulatory Review Period: Defines the regulatory review period for calculating patent term extensions and sets rules for due diligence during the application process.

Conclusion:
The Drug Price Competition and Patent Term Restoration Act of 1984 is a landmark legislation that balances the need for accessible, affordable medications with the incentive for innovation. It has significantly impacted the pharmaceutical industry by fostering competition and ensuring that both innovator and generic drug companies have clear pathways to market. The above points are not exhaustive; for comprehensive understanding, the full text of the Act should be consulted.

【文件概要】

该指南以问答形式阐明美国FDA关于新药申请（NDA）或补充申请获得3年临床研究专营权的法定和监管标准。文件依据《联邦食品、药品和化妆品法案》（FD&C Act）第505(c)(3)(E)(iii)-(iv)及第505(j)(5)(F)(iii)-(iv)条款，系统解析三类核心条件：申请需包含非生物利用度研究的新临床研究数据；研究必须为批准所必需；研究需由申请人主导或资助。指南明确临床研究的定义涵盖人类受试者药物实验，排除仅使用安慰剂的试验，并区分生物利用度研究与临床研究。对于多队列或多治疗组研究，特定队列或治疗组若满足独立性、创新性及预设性要求，可单独作为新临床研究支持专营权。申请人需提交认证声明、文献检索清单及研究必要性论证，FDA将基于个案评估专营权资格，最终通过橙皮书公布专营权代码及期限。

【适用范围】

本文适用于美国FDA监管的化学药和生物制品，涵盖创新药、改良新药（505(b)(2)途径）及其补充申请，不涉及原料药或仿制药。适用企业包括开展NDA或补充申请的制药企业（如大型药企、Biotech），需涉及新临床研究且符合活性成分已获批的前提条件。

【影响评估】

本文为创新药企提供明确的专营权申请路径，强化数据独占期的法律确定性，可能延缓仿制药或505(b)(2)申请对相关适应症的竞争。企业需优化临床研究设计以满足“新临床研究”标准，并加强研究主导权及必要性的文档管理，以最大化专营权收益。

【实施建议】

• 注册：必读。需在NDA提交前完成专营权申请，包含认证声明、研究必要性论证及IND关联证明，按§314.50(j)要求通过电子提交网关递交。
• 临床：必读。设计研究时需确保非生物利用度属性，预设独立队列以支持专营权主张，保留研究主导权证明文件（如IND表单、财务支持记录）。
• 法务：必读。审核专营权申请材料的合规性，评估并购或授权研究中“前任利益”条款对专营权资格的影响。

以上仅为部分要点，请阅读原文，深入理解监管要求。